RxDoctor Payments Data

Edward Laporta, MD

Cardiovascular Disease · Drexel Hill, PANPI 1801869490

Payments from drug & device makers

$1,294in general payments, 2019–2025

Across 55 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$254
  • Johnson & Johnson$146
  • Boston Scientific$124
  • Kiniksa Pharmaceuticals International, PLC$103
  • Pfizer$85
  • E.r. Squibb & Sons, L.L.C.$82
  • plus $499 from 15 others

What the payments were for

  • Food & beverage$1,28199%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,294 in reported general payments places this provider in the 40th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$146,242
Medicare patients
473
Services billed
1,994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban251$323,216
XareltoRivaroxaban53$68,152
FarxigaDapagliflozin Propanediol41$50,464
EntrestoSacubitril/Valsartan19$27,714
JardianceEmpagliflozin25$23,781
Repatha SureclickEvolocumab14$18,174
Atorvastatin Calcium854$13,816
BrilintaTicagrelor22$12,487
Repatha SyringeEvolocumab19$12,399
VascepaIcosapent Ethyl18$11,864
Metoprolol Succinate382$7,270
Rosuvastatin Calcium244$5,237
Ezetimibe195$5,117
Amlodipine Besylate412$4,011
Losartan Potassium271$3,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$85$323,216251 claims
Johnson & JohnsonXarelto$146$68,15253 claims
NovartisEntresto$38$27,71419 claims
Boehringer IngelheimJardiance$17$23,78125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Drexel Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →